SCHEMBL200911

SCHEMBL200911

C[Si](C)(C)CCOCn1ccccc1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
MITF O75030 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
DUT P33316 2/20 0.38
EGFR P00533 1/20 0.38
IGF1R P08069 1/20 0.38
SRC P12931 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
FLT3 P36888 1/20 0.38
EPHB4 P54760 1/20 0.38
TEK Q02763 1/20 0.38
DGAT1 O75907 2/20 0.37
PSMB1 P20618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9752623 0.82 POLB (0.48) NPC1MITFLMNATP53RAB9A
SCHEMBL9680970 0.79 NPC1 (0.43) NPC1MITFLMNATP53RAB9A
SCHEMBL29228942 0.78 DGAT1 (0.40) NPC1DUTEGFRIGF1RSRC
SCHEMBL31006173 0.78 DGAT1 (0.36) NPC1DUTEGFRIGF1RSRC
SCHEMBL30165149 0.78 ALDH1A1 (0.40) NPC1SMN1; SMN2DUTEGFRIGF1R
SCHEMBL4473921 0.77 MAPK14 (0.40) NPC1EGFRIGF1RSRCFLT4
SCHEMBL28668524 0.77 DGAT1 (0.40) NPC1DUTEGFRIGF1RSRC
SCHEMBL28692475 0.77 DGAT1 (0.37) NPC1DUTEGFRIGF1RSRC
SCHEMBL28471190 0.77 DGAT1 (0.42) NPC1DUTEGFRIGF1RSRC
SCHEMBL28821239 0.77 DUT (0.38) NPC1DUTEGFRIGF1RSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088926-B2 Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity JENRIN DISCOVERY, INC. (US) 2012-01-03 US disclosed
US-20080287505-A1 SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287505-A1 SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY CNR2, CNR1, GPR119 NPC1 1331/4885MITF 1947/4885LMNA 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.